CELL AND GENE THERAPY

Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index

Brooklyn ImmunoTherapeutics, Inc. | December 18, 2021

Brooklyn ImmunoTherapeutics, Inc. on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, announces that Brooklyn has been added to the ICE Biotechnology Index following the December 20, 2021 reconstitution.

The continued recognition of Brooklyn among key biotechnology indices is encouraging and we continue to believe that our value proposition and approach to our business are being rewarded with these inclusions. We look forward to beginning the new year strong and are grateful to be included among the key players in the biotech sector,” 

 Brooklyn’s Chief Executive Officer and President Howard Federoff, M.D., Ph.D

The ICE Biotechnology Index tracks the performance of qualifying U.S.-listed biotechnology companies classified within the Biotechnology Sub-Industry Group of the ICE Uniform Sector Classification schema, which is a multi-asset class industry classification taxonomy developed by ICE. The index includes companies that are engaged in the research and development of therapeutic treatments but are not focused on the commercialization and mass production of pharmaceutical drugs. The index also includes companies that are engaged in the production of tools or systems that enable biotechnology processes.

About Brooklyn ImmunoTherapeutics
Brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases.

Brooklyn’s most advanced program is IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.

Brooklyn has multiple next-generation cell and gene-editing therapies in preclinical development for various indications including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. 

Spotlight

The biopharmaceutical industry is at a pivotal time in medical discovery, which has enormous potential to further revolutionize the treatment of costly and debilitating diseases like Alzheimer’s, cancer, heart disease, and hepatitis C. Our ability to harness recent scientific advances continues to accelerate, and the potential benefits to patients are becoming clearer.


Other News
CELL AND GENE THERAPY

Enzychem Lifesciences Announces Formation of Corporate Advisory Committee

Enzychem Lifesciences | March 03, 2022

Enzychem Lifesciences a clinical-stage biotechnology company, announced today the formation of its Corporate Advisory Committee. Composed of four eminent physicians, its mission is to support and guide corporate activities including technology transfer for its lead compound, EC-18, seeking strategic partnerships, and preparing U.S. phase 3 clinical trials to successfully commercialize EC-18. After the completion of its phase 2 U.S. clinical trial with EC-18 in Chemoradiation–induced Oral Mucositis (CRIOM), Enzychem is actively negotiating licensing deals with several partnering candidates while also preparing a phase 3 trial under a US FDA IND. To reinforce such corporate initiatives, and to start supporting the company’s next stage activities, Enzychem has formed the Corporate Advisory Committee. Enzychem Lifesciences recognizes the need for engagement of key opinion leaders at an earlier stage in the process of developing new therapeutics for a large population with high unmet needs such as Chemoradiation-induced Oral Mucositis (CRIOM). Enzychem is proactively bringing more experts to the company to strengthen its new drug development capabilities. The newly appointed corporate advisors will actively influence the development of strong business strategies to successfully meet corporate objectives. The four physicians appointed are Dr. Alexander Fleming, a former FDA reviewer and supervisory medical officer, as head of the metabolic group, Dr. Frank Castellana, a market value assessment expert, Dr. Joe McMenamin, a health lawyer, and Dr. Richard Hamrick, a former healthcare provider executive. Based on their extensive experience, the corporate advisors will assist Enzychem in accomplishing its business milestones. For two years, until 2018, Dr. Fleming served as Enzychem’s Chief Technology Officer (CTO). During his term, Dr. Fleming had recommended CRIOM as the lead indication for EC-18 and introduced Dr. Steve Sonis of Harvard School of Dental Medicine as Enzychem’s key advisor for the U.S. phase 2 CRIOM Study. Enzychem Lifesciences is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for patients with unmet medical needs in oncology, metabolic, and inflammatory diseases. Founded in 1999, the company’s lead compound, EC-18, acts as an immunomodulator, facilitating the resolution of inflammation and the early return to immune homeostasis. Enzychem is headquartered in South Korea, with an office in the United States.

Read More

INDUSTRIAL IMPACT

IFF to Acquire Health Wright Products

IFF | February 17, 2022

IFF announced that it has entered into an agreement to acquire Health Wright Products, LLC (HWP), a leader in formulation and capsule manufacturing for the dietary supplement industry. Founded in 1995, HWP is located in Clackamas, Oregon, USA, and is a privately-owned and long-time business partner of IFF’s Health & Biosciences probiotics business. HWP is a global leader in the consumer Health and Nutrition industries, providing the highest-quality nutritional supplements. Using state-of-the-art processes and equipment, HWP manufactures custom formulations, and delivers encapsulation and packaging to meet the industries’ more exacting requirements for probiotic products. With over 165,000 ft2 (15,328 m2) of manufacturing space, the company generated approximately $100 million in annual revenue in 2021 and employed over 225 people who will continue with the company after the sale. The acquisition will bring formulation and finished format capabilities to IFF’s Health & Biosciences probiotics, natural extracts and botanicals businesses, allowing for innovation in custom formulation and combination products through joint capabilities. “Today’s announcement is driven by our commitment to enhance long-term value to our partners and customers. Producing thousands of unique and complex formulations for the industry’s most trusted brands, Health Wright Products formulation and finished format abilities will allow us to develop new and customized solutions and formats for a broad base of customers,” Simon Herriott, President, IFF’s Health & Biosciences division “We look forward to joining IFF’s Health & Biosciences division. Health Wright Products best-in-class quality manufacturing and formulation capabilities, combined with the strong biotech innovation pipeline of IFF’s Health & Biosciences, is an exciting proposition for our customers and employees,” said Mark Wright, President, Health Wright Products. The sale is expected to close in the first quarter of 2022, subject to customary closing conditions, and regulatory clearances. Financial terms of the deal have not been disclosed. About Health Wright Products, LLC. At Health Wright Products, a contract manufacture of dietary supplements, Quality, Service and Value have been the driving principles in our commitment to exceeding customers’ expectations. We partner with brands committed to the same driving principles for themselves and their customers. As a global industry leader, we leverage innovation, technology, experience and capacity to offer better solutions to current and emerging products. Providing better health by Encapsulating Excellence. About IFF’s Health & Biosciences division Inspired by nature and distinguished by its world-class bioscience and microbiome capabilities, IFF’s Health & Biosciences division is a leading innovation partner for customers across a broad range of consumer product, industrial and agricultural sectors. IFF’s Health & Biosciences division works closely with our customers to enhance products – and their processes – to deliver safer, healthier and more sustainable solutions. Welcome to IFF At IFF an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves.

Read More

DIAGNOSTICS

RQ Bio Launches with Goal to Transform Treatment and Prevention of Viral Infectious Diseases Through Antibody Technologies

RQ Bio | May 17, 2022

RQ Bio today emerges from stealth mode announcing its launch as a new UK-based biotechnology company following the completion of a successful licensing deal with AstraZeneca for RQ Bio's existing mAbs against SARS-CoV-2. The Company, which is headquartered in London, is dedicated to developing treatments and preventative therapies based on potent broad-spectrum mAbs to provide instant and long-lasting immunity for vulnerable people at risk of severe disease or death from existing, emerging and new viral infections. To maximise and accelerate patient impact, the company will continue to be supported by its collaborations with its scientific co-founders, the University of Oxford and leading UK medical research charity LifeArc. Professor Gavin Screaton, Head of the Medical Sciences Division at the University of Oxford, will continue to advise in his capacity as scientific and medical co-founder, as will Clare Terlouw, Head of LifeArc Ventures and UK BIA board member, as a member of the Board of Directors. Our vision is to build on our successful debut with neutralising antibody therapy for SARS-CoV-2 and develop innovative medicines to address current and evolving unmet needs in other viral infectious diseases, By combining our expertise and innovative excellence in core areas we have created a smarter approach to antibody generation making us uniquely positioned to deliver fast patient impact." Hugo Fry, CEO of RQ Bio. LifeArc is committed to backing leading UK academics and scientists, and we were inspired to fund RQ Bio because of the exceptional group of founders who are so passionately dedicated to finding new treatments and preventative therapies in areas of high unmet patient need, LifeArc provided support from across the Charity, including the venture team, scientific labs and other in-house experts to help RQ Bio execute on its business plan, and we look forward to further supporting RQ Bio as it becomes a world-leading infectious disease company." Clare Terlouw, Head of LifeArc Ventures. About RQ Bio RQ Bio's mission has been to develop medicines based on potent broad-spectrum mAbs to provide instant and long-lasting immunity for vulnerable people at risk of severe disease or death from current and future variants of viral infections. RQ Bio has achieved this by combining innovative excellence in core areas to create a smarter approach to antibody generation. RQ Bio has multiple sources of leads and a deep collaboration with the University of Oxford. RQ Bio was founded by scientific experts previously involved with the UK BIA Antibody Taskforce, which worked to build a community of infectious disease antibody experts focussed on the development of rapid and efficient delivery of highly potent neutralising antibodies to help support the UK COVID-19 response. About AstraZeneca Licensing Deal Under the terms of the agreement, RQ Bio has granted AstraZeneca an exclusive worldwide licence to develop, manufacture and commercialise RQ Bio's exisiting early stage mAbs against SARS-CoV-2 and a right of first refusal to take an exclusive licence in respect of any additional mAbs against SARS-CoV-2. RQ Bio will receive upfront and milestone payments of up to $157 million and will be eligible to receive single digit royalties on sales. The successful licensing deal was supported by Oxford University Innovation (OUI), a wholly-owned subsidiary of the University of Oxford that manages the University's technology transfer and consulting activities, who worked efficiently and creatively with all parties on the corresponding technology licences and the filing of intellectual properties.

Read More

INDUSTRIAL IMPACT

Aanika Biosciences First Biotech Company to Receive Bermuda Monetary Authority’s Approval for Reinsurance Innovation Hub

Aanika Biosciences, | February 25, 2022

Aanika Biosciences, an emerging biotech company using microbial based technologies to protect the safety and security of our food system, announced today it has received acceptance into the Bermuda Monetary Authority’s (BMA) Innovation Hub. The program will allow reinsurers to explore how the application of Aanika’s traceability and prevention technology can help reduce the magnitude and size of claims while lowering premiums and expanding protection for the food and agriculture industry. Reinsurance is an almost $500 billion global industry that allows insurance carriers to offload portfolio risks to reinsurers and hedge funds. Aanika estimates its technology could help in the underwriting of nearly $100 billion in premiums linked to contamination, recalls, crop insurance as well as non-safety related claims linked to ESG practices and general product liability. Bermuda is one of the largest hubs for the reinsurance market in the world and the center of innovation in the space. Prior to co-founding Aanika, CEO Vishaal Bhuyan spent more than a decade in finance focused on investing, managing and co-authoring multiple books on insurance-linked derivatives related to human longevity, overfishing and water scarcity. “Climate change will wreak havoc on our food system – potentially accelerating contamination outbreaks, diseases and natural disasters that are damaging and outright destroying crops around the world. ,” says Bhuyan. “ The insurance industry is not yet equipped to handle the volatility of risk and magnitude of loss - and is operating with a massive blind spot. In recent years insurers have adopted machine learning, satellite data and blockchain technologies to increase efficiency and more accurately price risks, but this will be the first use of synthetic biology to better prepare and protect themselves and their policyholders.” The proof-of-concept initiative approved by the BMA will enable Aanika to partner with insurance carriers to develop ‘test policies’ for the U.S. food and agricultural market that mandate applying the microbial technology in their supply chain. This improved ability to distinguish identical commodities from each other will increase transparency throughout the claims process beyond what is possible with digital technologies alone. Aanika co-founder and Chief Science Officer Dr. Ellen Jorgensen says this is a unique and unprecedented opportunity to unlock the potential of synthetic biology. “We need stable, scalable, actionable solutions now to build a more resilient global food supply, which means finding inventive ways of looking at the problem,” says Dr. Jorgensen. “The Aanika science team has developed a way to adapt nature to meet this challenge, and it will be exciting to see how leveraging it in an unconventional way like reinsurance can have immediate as well as long-term benefits.” By tapping into the reinsurance industry, Aanika will be able to commercialize biological innovations in ways that have never been done before. Aanika’s goal is to capture a fee on every policy that is essentially microscopically tethered to the product while using its growing pipeline of “secondary functions” to further enhance the stability and shelf life of said product – reducing the probability and magnitude of a claim. About Aanika Biosciences Aanika Biosciences was co-founded in 2018 by Vishaal Bhuyan after he personally experienced the consequences of ordering fresh, ethically sourced seeds and receiving stale, contaminated products instead. He made it his mission to create a safer food supply by finding a way to track, trace and authenticate products. Aanika’s customized microbial-based tags help companies gain valuable insights about their supply chains, help their customers make better consumption choices, and create a more sustainable world. About Bermuda Monetary Authority The Bermuda Monetary Authority (Authority or BMA) regulates Bermuda’s financial services sector. The Authority was established by statute in 1969. Its role has evolved over the years to meet changing needs in the financial services sector. Today it supervises, regulates and inspects financial institutions operating in the jurisdiction. It also issues Bermuda’s national currency, manages exchange control transactions, assists other authorities with the detection and prevention of financial crime, and advises Government on banking and other financial and monetary matters.

Read More

Spotlight

The biopharmaceutical industry is at a pivotal time in medical discovery, which has enormous potential to further revolutionize the treatment of costly and debilitating diseases like Alzheimer’s, cancer, heart disease, and hepatitis C. Our ability to harness recent scientific advances continues to accelerate, and the potential benefits to patients are becoming clearer.

Resources